BLA 125388 · Seattle Genetics
Adcetris
Brentuximab Vedotin · Injection · CD30-directed Immunoconjugate
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Aug 19, 2011
Approved uses
9
Original approval plus efficacy supplements
Registered trials
189
19 Phase 3, 23 recruiting
FAERS reports
10,402
9,478 serious, 1,994 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS [see Warnings and Precautions (5.9) , Adverse Reactions (6.1) ] . WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) See full prescribing information for complete boxed warning. JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS ( 5.9 , 6.1 ).
What it is approved for
From the label in effect Nov 11, 2025.
ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell...
Mechanism: CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of sALCL cells and on Hodgkin Reed-Sternberg (HRS) cells in cHL. CD30 is variably expressed in other T-cell lymphomas. Expression of CD30 on healthy tissue and cells is limited. In vitro data suggest that signaling through CD30-CD30L binding may affect cell survival and proliferation. Brentuximab vedotin is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against CD30. The small molecule, MMAE, is a microtubule-disrupting agent. MMAE is covalently attached to the antibody...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 11, 2025 Supplement 108 · Efficacy OrphanLabelLetterReview
- Jun 14, 2023 Supplement 107 · Efficacy OrphanLetterLabel
- Nov 10, 2022 Supplement 106 · Efficacy · priority review LabelLetter
- Nov 16, 2018 Supplement 99 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Mar 20, 2018 Supplement 97 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Nov 9, 2017 Supplement 94 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Aug 17, 2015 Supplement 80 · Efficacy · priority review OrphanLabelLetter
- Aug 19, 2011 Supplement 6 · Efficacy · priority review Accelerated approvalOrphan
- Aug 19, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewOther Important Information from FDA
1 products under this application
- ADCETRIS · BRENTUXIMAB VEDOTIN 50MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Brentuximab Vedotin" as an intervention, any sponsor and status, largest first.
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05675410 · 1,875 participants (planned) · Start May 11, 2023 · Primary completion Apr 28, 2031
Drug: Bleomycin Sulfate; Brentuximab Vedotin and 11 more · For: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 419 sites in all
- HD21 for Advanced StagesPivotal-lookingStatus unknown
University of CologneAcademic, hospital or other
NCT02661503 · 1,500 participants · Start Jul 2016 · Primary completion Dec 2022
Drug: Bleomycin; Etoposide and 8 more · For: Classical Hodgkin Lymphoma
Sites: Cologne, Germany
- A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin LymphomaPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT01712490 · 1,334 participants · Start Nov 9, 2012 · Primary completion Apr 20, 2017
Drug: brentuximab vedotin; doxorubicin and 3 more · For: Hodgkin Lymphoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Tucson, Arizona · 215 sites in all
- Brentuximab Vedotin in Early Stage Hodgkin LymphomaPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT04685616 · 1,042 participants (planned) · Start Apr 14, 2022 · Primary completion Sep 2030
Drug: Doxorubicin; Bleomycin and 4 more · For: Hodgkin Lymphoma
Sites: Stanford, California; Miami, Florida; New York, New York · 72 sites in all
- Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03907488 · 994 participants · Start Aug 29, 2019 · Primary completion Mar 31, 2024
Drug: Brentuximab Vedotin; Dacarbazine and 5 more · For: Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 728 sites in all
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin LymphomaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02166463 · 600 participants · Start Mar 19, 2015 · Primary completion Dec 31, 2021
Drug: Bleomycin Sulfate; Brentuximab Vedotin and 6 more · For: Ann Arbor Stage IIB Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma and 3 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 199 sites in all
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell LymphomasPivotal-lookingCompleted
Seagen Inc.Pfizer (PFE)
NCT01777152 · 452 participants · Start Jan 31, 2013 · Primary completion Aug 15, 2018
Drug: brentuximab vedotin; doxorubicin and 3 more · For: Anaplastic Large-Cell Lymphoma; Non-Hodgkin Lymphoma; T-Cell Lymphoma
Sites: Gilbert, Arizona; Duarte, California; Stanford, California · 144 sites in all
- Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaPivotal-lookingNot yet recruiting
National Cancer Institute (NCI)NIH
NCT07572123 · 374 participants (planned) · Start Dec 4, 2026 · Primary completion Mar 31, 2029
Drug: Brentuximab Vedotin; High Dose Chemotherapy and 2 more · For: Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,358
- febrile neutropenia776
- neuropathy peripheral725
- pyrexia694
- neutropenia599
- death594
- hodgkin^s disease462
- nausea407
- anaemia399
- thrombocytopenia388
- diarrhoea387
- drug ineffective378
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 16 |
| 2012 | 151 |
| 2013 | 182 |
| 2014 | 294 |
| 2015 | 377 |
| 2016 | 453 |
| 2017 | 609 |
| 2018 | 677 |
| 2019 | 887 |
| 2020 | 940 |
| 2021 | 927 |
| 2022 | 821 |
| 2023 | 855 |
| 2024 | 1,517 |
| 2025 | 1,040 |
| 2026 | 656 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Adcetris (Brentuximab Vedotin)
2024 spending
$3.5M
Beneficiaries
25
106 claims
Per beneficiary
$140,843
$11,107.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,207,676 |
| 2021 | $2,395,839 |
| 2022 | $3,044,765 |
| 2023 | $3,056,726 |
| 2024 | $3,521,063 |
Part B: Adcetris (Brentuximab Vedotin) · HCPCS J9042
2024 spending
$187M
Beneficiaries
1,363
6,255 claims
Per beneficiary
$137,180
2024 ASP limit $235.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $161,368,351 |
| 2021 | $164,383,360 |
| 2022 | $186,209,799 |
| 2023 | $193,419,173 |
| 2024 | $186,976,535 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Herrera AF, LeBlanc M, Castellino SM, et al. · N Engl J Med 2024 · Multicenter Study, Randomized Controlled Trial
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S, O'Connor OA, Pro B, et al. · Ann Oncol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
Bartlett NL, Hahn U, Kim WS, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Multicenter Study
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, et al. · Lancet 2019 · Clinical Trial, Phase III, Multicenter Study
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, et al. · J Clin Oncol 2021 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Seattle Genetics
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.